It may sound harsh, but drug candidates that are bound to be poor performers should be identified sooner rather than later—and ruthlessly eliminated from development. Granted, early in development, ...

Can you give a brief overview of Lonza, the markets you serve and the types of products that you produce? Lonza is a large, multinational corporation serving the entire pharmaceutical product ...

Cell imaging is an increasingly useful tool in predictive ADME/Tox strategies, according to Karen Tilmant, Ph.D., research scientist, investigative nonclinical safety, at UCB Pharma, who spoke at ...

BioIVT, a leading provider of biospecimens and ADME-Tox research products and services for drug and diagnostic development, today announced that it will be hosting an Advanced In Vitro ADME Strategies ...